1. Home
  2. TJGC vs VERU Comparison

TJGC vs VERU Comparison

Compare TJGC & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TJGC Group Limited Ordinary Shares

TJGC

TJGC Group Limited Ordinary Shares

N/A

Current Price

$6.11

Market Cap

50.9M

ML Signal

N/A

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.25

Market Cap

40.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TJGC
VERU
Founded
2022
1971
Country
Hong Kong
United States
Employees
19
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.9M
40.9M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
TJGC
VERU
Price
$6.11
$2.25
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$22.50
AVG Volume (30 Days)
1.5M
63.0K
Earning Date
08-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.49
$0.36
52 Week High
$2.18
$4.59

Technical Indicators

Market Signals
Indicator
TJGC
VERU
Relative Strength Index (RSI) 93.51 46.97
Support Level $0.80 $2.12
Resistance Level N/A $2.67
Average True Range (ATR) 0.49 0.13
MACD 0.31 0.02
Stochastic Oscillator 90.14 55.71

Price Performance

Historical Comparison
TJGC
VERU

About TJGC TJGC Group Limited Ordinary Shares

TJGC Group Ltd, formerly CTRL Group Ltd is an integrated marketing and advertising services provider in Hong Kong specializing in mobile games promotion for the local market. It provide services to mobile game developers, principally developers of mobile gaming applications or apps that gamers download from the developers' websites and applicable mobile operating systems, such as Apple Store or Android Google Play Store.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: